An Open-label Single Center Study to Characterize the Absorption, Distribution, Metabolism, and Elimination (ADME) of Patupilone (EPO906) After a Single Intravenous Administration of 10 mg/m2 [14C] Patupilone in Patients With Advanced Solid Tumor Malignancies.
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2015
At a glance
- Drugs Patupilone (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Novartis
- 10 Nov 2009 Actual patient number (5) added as reported by ClinicalTrials.gov.
- 10 Nov 2009 Actual end date (1 Nov 2006) added as reported by ClinicalTrials.gov.
- 28 Jan 2008 Status changed from in progress to completed.